G Pelosi

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. ncbi Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Via G Ripamonti, 435, I 20141 Milan, Italy
    Lung Cancer 42:203-13. 2003
  2. pmc Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer
    G Pelosi
    Department of Pathology and Laboratory Medicine, University of Milan School of Medicine, Italy
    Br J Cancer 88:537-47. 2003
  3. ncbi Pulmonary epithelial-myoepithelial tumor of unproven malignant potential: report of a case and review of the literature
    G Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Italy
    Mod Pathol 14:521-6. 2001
  4. pmc Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients
    G Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Br J Cancer 81:1213-21. 1999
  5. ncbi Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer
    F Toffalorio
    Clinical Pharmacology and New Drug Development Unit, European Institute of Oncology, Milan, Italy
    Pharmacogenomics J 10:180-90. 2010
  6. pmc Fluoro-deoxi-glucose uptake and angiogenesis are independent biological features in lung metastases
    G Veronesi
    Department of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Br J Cancer 86:1391-5. 2002
  7. ncbi Synchronous pleuro - renal solitary fibrous tumors: a new clinical-pathological finding
    F Petrella
    Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Minerva Chir 64:669-71. 2009
  8. ncbi Low morbidity of bronchoplastic procedures after chemotherapy for lung cancer
    G Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Lung Cancer 36:91-7. 2002
  9. ncbi Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung
    G Pelosi
    Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Am J Surg Pathol 25:363-72. 2001
  10. ncbi CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours
    G Pelosi
    Divisione di Anatomia Patologica e Medicina di Laboratorio, Istituto Europeo di Oncologia, Milano, Italy
    Virchows Arch 437:270-4. 2000

Detail Information

Publications77

  1. ncbi Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Via G Ripamonti, 435, I 20141 Milan, Italy
    Lung Cancer 42:203-13. 2003
    ..Targeting the fascin pathway could be a novel therapeutic strategy of pulmonary carcinoids...
  2. pmc Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer
    G Pelosi
    Department of Pathology and Laboratory Medicine, University of Milan School of Medicine, Italy
    Br J Cancer 88:537-47. 2003
    ..Targetting the fascin pathway could be a novel therapeutic strategy of NSCLC...
  3. ncbi Pulmonary epithelial-myoepithelial tumor of unproven malignant potential: report of a case and review of the literature
    G Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Italy
    Mod Pathol 14:521-6. 2001
    ..In addition, we first introduce p63 as a novel marker for highlighting the myoepithelial cells of the respiratory tract and speculate on the role of these cells in the development of this unusual tumor...
  4. pmc Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients
    G Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Br J Cancer 81:1213-21. 1999
    ....
  5. ncbi Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer
    F Toffalorio
    Clinical Pharmacology and New Drug Development Unit, European Institute of Oncology, Milan, Italy
    Pharmacogenomics J 10:180-90. 2010
    ..These data suggest a similar genetic susceptibility to gemcitabine-cisplatin regimens for squamous cell and adenocarcinoma and support the use of both lymph node and primary tumor for the expression profiling of NSCLC...
  6. pmc Fluoro-deoxi-glucose uptake and angiogenesis are independent biological features in lung metastases
    G Veronesi
    Department of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Br J Cancer 86:1391-5. 2002
    ..Glucose uptake and angiogenesis appear to be independent biological features in lung metastasis. This observation may have implications for future antiangiogenic therapies...
  7. ncbi Synchronous pleuro - renal solitary fibrous tumors: a new clinical-pathological finding
    F Petrella
    Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Minerva Chir 64:669-71. 2009
    ..After a one-year follow-up no recurrence was detected in the left hemithorax and the renal lesion remained stable...
  8. ncbi Low morbidity of bronchoplastic procedures after chemotherapy for lung cancer
    G Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Lung Cancer 36:91-7. 2002
    ..To evaluate if induction chemotherapy, with or without irradiation, represents an additional risk factor for early and late morbidity and perioperative mortality in bronchoplastic procedures for lung cancers...
  9. ncbi Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung
    G Pelosi
    Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Am J Surg Pathol 25:363-72. 2001
    ..Our findings suggest that TTF-1 could be involved in the development of small pulmonary adenocarcinomas, but it has not prognostic implications in patients with stage I NSCLC...
  10. ncbi CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours
    G Pelosi
    Divisione di Anatomia Patologica e Medicina di Laboratorio, Istituto Europeo di Oncologia, Milano, Italy
    Virchows Arch 437:270-4. 2000
    ....
  11. pmc Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group
    T De Pas
    Division of Medical Oncology, European of Oncology, Via Ripamonti, Milan, Italy
    Br J Cancer 88:645-7. 2003
    ..We report on two patients with fast-growing recurrences of AF resistant to EBRT who obtained protracted clinical benefits with (90)Y-DOTATOC. (90)Y-DOTATOC should be further investigated in this setting...
  12. doi Genomic characterization of asymptomatic CT-detected lung cancers
    E Belloni
    Department of Experimental Oncology, European Institute of Oncology, Milan, Italy
    Oncogene 30:1117-26. 2011
    ....
  13. ncbi Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy
    G Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Milan, Italy
    Q J Nucl Med Mol Imaging 50:272-87. 2006
    ....
  14. pmc Metastasis to the right stellate ganglion and vagal nerve: pathological alterations causing sudden death. A case report
    F Maffini
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, G Ripamonti 435, 20141 Milan, Italy
    Acta Otorhinolaryngol Ital 32:263-5. 2012
    ....
  15. pmc Sebaceous lymphadenoma of salivary gland: a case report and a review of the literature
    F Maffini
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan, School of Medicine, Milan, Italy
    Acta Otorhinolaryngol Ital 27:147-50. 2007
    ....
  16. ncbi Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours
    D Ravizza
    European Institute of Oncology, Division of Endoscopy, Via Ripamonti 435, Milan, Italy
    Dig Liver Dis 39:537-43. 2007
    ..Based on the favourable behaviour of this neoplasm, we performed an endoscopic and clinical follow-up in 11 patients affected by type 1 gastric neuroendocrine tumours, avoiding any specific treatment...
  17. ncbi Challenging diagnosis of an unusual solitary pulmonary nodule
    D Galetta
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Thorac Cardiovasc Surg 55:123-5. 2007
    ..It is important not to confuse these two diseases as this will prevent inappropriate medical treatment. Limited surgery is indicated for the treatment of these circumscribed lesions...
  18. ncbi Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 1:468-77. 2006
    ..Few data are available on the prevalence and clinicopathological meaning of CD99, the transmembrane product of the pseudoautosomal MIC2 gene, in pulmonary neuroendocrine tumors...
  19. ncbi Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Cancer 97:2487-97. 2003
    ..However, little is known regarding the prevalence and clinical implications of NE differentiation in patients with Stage I NSCLC...
  20. ncbi Prognostic role of lymph node involvement in lung metastasectomy
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Cardiovasc Surg 133:967-72. 2007
    ..We assessed the prognostic value of lymph node status in lung metastasectomy and the prevalence of unexpected mediastinal lymph node involvement after lymph node sampling or dissection...
  21. ncbi Results of chest wall resection for recurrent or locally advanced breast malignancies
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 16:297-302. 2007
    ....
  22. ncbi Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib
    Giuseppe Curigliano
    Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology and University of Milan School of Medicine, Milano, Italy
    Prostate 67:603-4. 2007
    ..To our knowledge no data have been reported on EGFR gene mutations in hormone refractory prostate cancer (HRPC)...
  23. ncbi Expression of p63 in thymomas and normal thymus
    Jorge Dotto
    Department of Pathology, Yale New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA
    Am J Clin Pathol 127:415-20. 2007
    ..All thymomas (including thymic carcinomas) were positive for p63 regardless of type. Most of the epithelial cells of the normal thymus were also positive for this marker...
  24. ncbi Invited commentary
    Giuseppe Pelosi
    Istituto Europeo di Oncologia, Via G Ripamonti 435, Milan, I 20141 Italy
    Ann Thorac Surg 83:214-5. 2007
  25. ncbi Erlotinib-induced breast cancer regression
    Chiara Catania
    Medical Care Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Pharmacother 40:2043-7. 2006
    ..To report a case of erlotinib-induced breast cancer regression...
  26. ncbi A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, and University of Milan School of Medicine, Milan, Italy
    J Natl Cancer Inst 95:779-90. 2003
    ....
  27. ncbi A primary pure yolk sac tumor of the lung exhibiting CDX-2 immunoreactivity and increased serum levels of alkaline phosphatase intestinal isoenzyme
    Giuseppe Pelosi
    Division of Pathology, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Surg Pathol 14:247-51. 2006
    ..The pathologist should be aware of yolk sac tumor arising in the lung and that alkaline phosphatase intestinal isoform could become an additional serum marker for such a tumor...
  28. ncbi Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma
    Nicola Fazio
    Acta Oncol 45:627-9. 2006
  29. ncbi Immunoreactivity for sex steroid hormone receptors in pulmonary hamartomas
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Voa G Ripamonti 435, I 20141 Milan, Italy
    Am J Surg Pathol 30:819-27. 2006
    ..In conclusion, sex steroid hormone receptor expression is a nonrandom event in pulmonary hamartoma, and may be related to the development and growth of this tumor...
  30. ncbi Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancer
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 2:131-4. 2007
    ....
  31. ncbi 3q26 Amplification and polysomy of chromosome 3 in squamous cell lesions of the lung: a fluorescence in situ hybridization study
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine and Cancer Genetic Unit, IFOM Foundation FIRC Institute of Molecular Oncology Foundation, Milan, Italy
    Clin Cancer Res 13:1995-2004. 2007
    ....
  32. ncbi Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging
    Giacomo Puppa
    Division of Pathology, CRO National Cancer Institute, Aviano, Italy
    Mod Pathol 20:843-55. 2007
    ..Our findings suggest that pericolonic tumor deposits are a destructive type of venous invasion different from other types of vessel involvement, and that these lesions may rather be included in the M category for staging purposes...
  33. ncbi Progesterone receptor immunoreactivity in minute meningothelioid nodules of the lung
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Via G Ripamonti 435, 20141 Milan, Italy
    Virchows Arch 440:543-6. 2002
    ..This finding corroborates the view that these proliferations exhibit arachnoid cell-like differentiation and suggests a role for sex-steroid hormones in the control of their growth...
  34. ncbi Late events and clinical prognostic factors in stage I non small cell lung cancer
    Felice Pasini
    Cattedra di Oncologia Medica, Universita di Verona, Verona, Italy
    Lung Cancer 37:171-7. 2002
    ..In conclusion: this study found a non-negligible proportion of late events and identified some prognostic factors (PS, presence of symptoms and large cell histology) using information obtained from routine data...
  35. ncbi High-dose chemotherapy in small cell lung cancer
    Felice Pasini
    Cattedra di Oncologia Medica, Universita di Verona, Italy
    Tumori 88:179-86. 2002
    ..Nowadays, some interest is emerging again due to the improvements in supportive care such as the availability of hematopoietic growth factors and the peripheral blood progenitor cells (PBPC)...
  36. doi Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program
    Giulia Veronesi
    Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Cardiovasc Surg 136:611-7. 2008
    ..We evaluated the pitfalls, difficulties, and sources of mistakes in the management of lung nodules detected in volunteers in the Cosmos single-center screening trial...
  37. doi Invited commentary
    Giuseppe Pelosi
    Istituto Europeo di Oncologia ed Università degli Studi di Milano, Via G Ripamonti, 435, Milan, Italy
    Ann Thorac Surg 86:1090-1. 2008
  38. ncbi Cetuximab for colorectal cancer
    Filippo Fraggetta
    N Engl J Med 358:1196; author reply 1196-7. 2008
  39. doi Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung
    Antonio Marchetti
    Clinical Research Center, Center of Excellence on Aging, University Foundation, Chieti, Italy
    Hum Mutat 29:609-16. 2008
    ..Such mutational events could represent an important step in the cancerogenesis of these tumors and may have potential implications for the selection of patients for targeted therapy...
  40. doi Genetic alterations in combined neuroendocrine neoplasms of the lung
    Tiziana D'Adda
    Department of Pathology and Laboratory Medicine, Section of Pathological Anatomy, University of Parma, Parma, Italy
    Mod Pathol 21:414-22. 2008
    ..The genetic differences observed provide the basis for the divergent differentiation and parallel the morphological differences in the two components of these combined neuroendocrine neoplasms...
  41. ncbi Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Virchows Arch 448:7-15. 2006
    ..It can be added to the panel of multiple genetic tracers to detect lung cancer in the plasma of patients, although, per se, it is not specific for this tumor...
  42. ncbi Computer-assisted image analysis of breast fine needle aspiration in a randomized chemoprevention trial of fenretinide vs. placebo in HRT users
    Davide Serrano
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Breast 17:91-7. 2008
    ..Digital nuclear morphometric analysis can capture subtle differences along neoplastic progression. Studies showed different profiles from normal to cancer lesions. Our goal is to utilize this method as biomarker in chemoprevention trials...
  43. ncbi Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening
    Giulia Veronesi
    Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Ann Thorac Surg 84:959-65; discussion 965-6. 2007
    ..We present results using positron tomography scanning (CT-PET) to evaluate LD-CT-detected lung nodules during the first year of the Continuing Observation of Smoking Subjects (COSMOS) early detection trial for lung cancer...
  44. ncbi Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    J Clin Oncol 25:4201-9. 2007
    ..We assessed the optimal biologic dose and schedule of tamoxifen in HRT users using surrogate end point biomarkers and menopausal symptoms...
  45. ncbi Images in pathology. Benign hyperplastic mesothelial cells in lymph node
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Surg Pathol 15:297-9. 2007
  46. ncbi Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Lung Cancer 53:111-5. 2006
    ..We retrospectively evaluated outcomes in a series of patients with a pathological diagnosis of large cell neuroendocrine lung carcinoma, who underwent lung resection. We also assessed the utility of chemotherapy in a small subgroup...
  47. ncbi Subclavicular recurrence of breast cancer: does surgery play a role?
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 15:649-53. 2006
    ..We conclude that the technique may be useful, in selected cases, for palliation only...
  48. ncbi Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer
    Lorenzo Spaggiari
    Department of Thoracic Surgery European Institute of Oncology, Milan, Italy
    Ann Thorac Surg 79:234-40. 2005
    ..The present study analyzed a single center's experience with this extended surgery, highlighting the surgery's technical aspects, postoperative outcomes, and oncologic results...
  49. ncbi Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare
    Tommaso De Pas
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 22:4966-70. 2004
    ....
  50. ncbi Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors
    Tiziana D'Adda
    Department of Pathology and Laboratory Medicine, Section of Pathological Anatomy, University of Parma, Parma, Italy
    Mod Pathol 18:795-805. 2005
    ....
  51. ncbi Lung cancers detected by screening with spiral computed tomography have a malignant phenotype when analyzed by cDNA microarray
    Fabrizio Bianchi
    Cancer Research UK Tumor Pathology Group, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 10:6023-8. 2004
    ..Spiral computed tomography (CT) can detect lung cancer at an early stage, but the malignant potential is unknown. The question is, as follows: do these small lesions have the same lethal potential as do symptomatic tumors?..
  52. ncbi Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Cancer 113:101-8. 2005
    ..Among neuroendocrine tumours, LCNEC show a slightly higher prevalence of either HER-2/neu gene amplification or protein overexpression...
  53. ncbi CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Via G Ripamonti 435, 20141 Milan, Italy
    Virchows Arch 445:449-55. 2004
    ..There was no association between CD117 immunoreactivity and survival in either small-cell carcinoma or large-cell neuroendocrine carcinoma patients...
  54. ncbi CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Mod Pathol 17:711-21. 2004
    ..Targeting the CD117 pathway could be a novel therapeutic strategy in a subset of pulmonary carcinomas...
  55. ncbi Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial
    Elton R Kisanga
    Hormone Laboratory, Haukeland University Hospital, Department of Medicine, and Centre for International Health, University of Bergen, Bergen, Norway
    Clin Cancer Res 10:2336-43. 2004
    ..Furthermore we studied tamoxifen effects on the cancer proliferation marker Ki-67, and on sex hormone-binding globulin (SHBG)...
  56. ncbi K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Mod Pathol 17:538-46. 2004
    ....
  57. ncbi Detecting lung cancer in plasma with the use of multiple genetic markers
    Francesca Andriani
    Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
    Int J Cancer 108:91-6. 2004
    ..2%) of stage I patients whose tumors had an alteration. These results provide the proof of principle that plasma DNA alterations are tumor-specific in most cases and support blood testing as a noninvasive strategy for early detection...
  58. ncbi p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    J Pathol 198:100-9. 2002
    ..Although p63 is likely to be involved in the development of pulmonary squamous cell carcinoma, it does not carry any prognostic implication for NSCLC patients...
  59. ncbi Quantification of free circulating DNA as a diagnostic marker in lung cancer
    Gabriella Sozzi
    Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 21:3902-8. 2003
    ..This study was designed to assess the sensitivity and specificity of a quantitative molecular assay of circulating DNA to identify patients with lung cancer and monitor their disease...
  60. ncbi Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, Institute of European Oncology and University of Milan School of Medicine, Italy
    Am J Surg Pathol 27:1203-15. 2003
    ....
  61. ncbi Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Milan, Italy
    Am J Surg Pathol 29:179-87. 2005
    ....
  62. ncbi Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
    Cristina Noberasco
    J Clin Oncol 23:921-2; author reply 922. 2005
  63. ncbi Langerhans' cell histiocytosis
    Nicola Fazio
    European Institute of Oncology, 20141 Milan, Italy
    Lancet 365:598. 2005
  64. ncbi Salivary gland-type tumors with myoepithelial differentiation arising in pulmonary hamartoma: report of 2 cases of a hitherto unrecognized association
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Am J Surg Pathol 30:375-87. 2006
    ....
  65. ncbi Histidine decarboxylase, DOPA decarboxylase, and vesicular monoamine transporter 2 expression in neuroendocrine tumors: immunohistochemical study and gene expression analysis
    Silvia Uccella
    Section of Anatomic Pathology, Dept of Human Morphology, University of Insubria and Ospedale di Circolo, Via Ottorino Rossi, 9 I 21100 Varese, Italy
    J Histochem Cytochem 54:863-75. 2006
    ..HDC should not be considered as a general endocrine marker and HDC IR in bronchial carcinoids and PDNECs of the lung can probably be attributed to a cross-reaction with DDC...
  66. ncbi Treatment of pulmonary metastases from primary intraosseous odontogenic carcinoma
    Domenico Galetta
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Lancet Oncol 7:272-3. 2006
  67. ncbi Images in pathology: micronodular epithelial hyperplasia in ectopic thymus
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Surg Pathol 14:73-4. 2006
  68. ncbi Superior vena cava replacement for lung cancer using a heterologous (bovine) prosthesis: preliminary results
    Lorenzo Spaggiari
    Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Cardiovasc Surg 131:490-1. 2006
  69. ncbi Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women
    Aliana Guerrieri-Gonzaga
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    J Clin Oncol 24:129-35. 2006
    ....
  70. ncbi Microallelotyping defines the monoclonal or the polyclonal origin of mixed and collision endocrine-exocrine tumors of the gut
    Daniela Furlan
    Department of Clinical and Biological Sciences, University of Insubria, Varese, Italy
    Lab Invest 83:963-71. 2003
    ....
  71. ncbi A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Virchows Arch 447:969-77. 2005
    ..A minor subset of these tumors shows beta-catenin nuclear accumulation in association with increased expression of MMP-7, but not of cyclin D1, independent of EGFR and HER-2 gene amplification or expression...
  72. ncbi Target-treatment and patients' selection: can we still neglect the timing of tissue collection?
    Tommaso De Pas
    J Clin Oncol 23:6274-5; author reply 6275-6. 2005
  73. ncbi Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung
    Guida Maria Portela-Gomes
    Unit of Pathology, Department of Genetics and Pathology, University Hospital, 751 85 Uppsala, Sweden
    Virchows Arch 446:604-12. 2005
    ..The expression of CgA epitopes and SV2 occurs in all NE tumors, differing between better differentiated and poorly differentiated tumors but not within the respective groups...
  74. ncbi Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung
    Giulia Veronesi
    Thoracic Surgery Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Lung Cancer 48:233-40. 2005
    ..In SCC patients, the magnitude of the hazard ratio was confirmed even if the precision of the estimate is decreased (p=0.06). In conclusion, T-CEA expression appears to be an important prognostic factor in early stage SSC of the lung...
  75. ncbi Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
    Filippo De Braud
    J Natl Cancer Inst 97:461-2; author reply 462-3. 2005
  76. ncbi Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Milan, Italy
    Cancer 103:1154-64. 2005
    ..To the authors' knowledge, little is known regarding the role of E-cadherin/beta-catenin system dysregulation in pulmonary neuroendocrine tumors...
  77. ncbi Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results
    Ugo Pastorino
    Division of Thoracic Surgery, Istituto Nazionale Tumori, Milan, Italy
    Lancet 362:593-7. 2003
    ..We investigated the efficacy of repeated yearly spiral CT and selective use of positron emission tomography (PET) in a large cohort of high-risk volunteers...